Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMNHTZI)

• Drug Name: Protriptyline Drug Info
• Synonyms: Amimetilina; Impril; Maximed; Novopramine; Protriptilina; Protriptylinum; Protryptyline; Rhotrimine; Triptil; Triptyl; Vivactil; Vivactyl; Triptil hydrochloride; Normethyl EX4442; Triadapin 5; Apo-Imipramine; Apo-Trimip; Novo-Doxepin; Novo-Tripramine; Protriptilina [INN-Spanish]; Protriptyline (INN); Protriptyline [INN:BAN]; Protriptylinum [INN-Latin]; Vivactil (TN); N-Methyl-5H-dibenzo[a,d]cycloheptene-5-propanamine; N-Methyl-5H-dibenzo[a,d]cycloheptene-5-propylamine; N-Methyl-5H-dibenzo(a,d)cycloheptene-5-propylamine; N-3-(5H-Dibenzo(a,d)cyclohepten-5-yl)propyl-N-methylamine; 3-(5H-Dibenzo[a,d]cyclohepten-5-yl)-N-methyl-1-propanamine; 3-(5H-dibenzo[a,d][7]annulen-5-yl)-N-methylpropan-1-amine; 5-(3-Methylaminopropyl)-5H-Dibenzo[a,d]cycloheptene; 5-(3-Methylaminopropyl)-5H-dibenzo(a,d)cycloheptene; 5H-Dibenzo[a, d]cycloheptene-5-propanamine, N-methyl-, hydrochloride; 7-(3-Methylaminopropyl)-1,2:5,6-dibenzocycloheptatriene

Indication

Disease Entry	ICD 11	Status	REF
Depression	6A70-6A7Z	Approved	[1]

• Therapeutic Class: Antidepressants
• Cross-matching ID:
  PubChem CID: 4976
  ChEBI ID: CHEMBL668
  CAS Number: CAS 438-60-8
  TTD Drug ID: DMNHTZI
  VARIDT Drug ID: DR00486
  ACDINA Drug ID: D00567

Molecule-Related Drug Atlas

Drug(s) Targeting Norepinephrine transporter (NET)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[6]
Amitriptyline	DMK7F9S	Depression	6A70-6A7Z	Approved	[7]
Imipramine	DM2NUH3	Depression	6A70-6A7Z	Approved	[8]
Desipramine	DMT2FDC	Attention deficit hyperactivity disorder	6A05.Z	Approved	[6]
Cocaine	DMSOX7I	Anaesthesia	9A78.6	Approved	[9]
Bupropion	DM5PCS7	Depression	6A70-6A7Z	Approved	[10]
Tapentadol hydrochloride	DMXLSH3	Acute pain	MG31	Approved	[11]
Venlafaxine	DMR6QH0	Anxiety disorder	6B00-6B0Z	Approved	[10]
Trimipramine	DM1SC8M	Major depressive disorder	6A70.3	Approved	[12]
Duloxetine	DM9BI7M	Depression	6A70-6A7Z	Approved	[13]

Drug(s) Transported By P-glycoprotein 1 (ABCB1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Amoxicillin	DMUYNEI	Acute otitis media	AB00	Approved	[14]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[15]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[16]
Folic Acid	DMEMBJC	Colorectal carcinoma		Approved	[17]
Fluorouracil	DMUM7HZ	Adenocarcinoma	2D40	Approved	[16]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[16]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[18]
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[16]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[19]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[20]

Drug(s) Affected By Proepiregulin (EREG)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[21]
Fexofenadine	DM17ONX	Allergic rhinitis	CA08.0	Approved	[4]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[22]
Lumiracoxib	DM1S4AG	Chronic renal failure	GB61.Z	Approved	[4]
Clavulanate	DM2FGRT	Bacteremia	1A73	Approved	[4]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[23]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[24]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[25]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[26]
Penbutolol	DM4ES8F	Hypertension	BA00-BA04	Approved	[4]

Drug(s) Affected By Antileukoproteinase (SLPI)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Primidone	DM0WX6I	Epilepsy	8A60-8A68	Approved	[4]
Fexofenadine	DM17ONX	Allergic rhinitis	CA08.0	Approved	[4]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[22]
Lumiracoxib	DM1S4AG	Chronic renal failure	GB61.Z	Approved	[4]
Clavulanate	DM2FGRT	Bacteremia	1A73	Approved	[4]
Rofecoxib	DM3P5DA	Osteoarthritis	FA00-FA05	Approved	[4]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[4]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[27]
Penbutolol	DM4ES8F	Hypertension	BA00-BA04	Approved	[4]
Nefazodone	DM4ZS8M	Major depressive disorder	6A70.3	Approved	[4]

Drug(s) Affected By Hepatocyte growth factor receptor (MET)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cabozantinib	DMIYDT4	Medullary thyroid gland carcinoma		Approved	[28]
Crizotinib	DM4F29C	Non-small-cell lung cancer	2C25.Y	Approved	[29]
Fexofenadine	DM17ONX	Allergic rhinitis	CA08.0	Approved	[4]
Lumiracoxib	DM1S4AG	Chronic renal failure	GB61.Z	Approved	[4]
Clavulanate	DM2FGRT	Bacteremia	1A73	Approved	[4]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[30]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[24]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[4]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[31]
Methylprednisolone	DM4BDON	Acute adrenal insufficiency		Approved	[30]

Drug(s) Affected By Phosphatidylcholine translocator ABCB4 (ABCB4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Paclitaxel	DMLB81S	Breast carcinoma		Approved	[32]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[33]
Methysergide	DM1EF73	Migraine	8A80	Approved	[5]
Clavulanate	DM2FGRT	Bacteremia	1A73	Approved	[34]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[35]
Lapatinib	DM3BH1Y	Breast cancer	2C60-2C65	Approved	[5]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[24]
obeticholic acid	DM3Q1SM	Primary biliary cholangitis	DB96.1	Approved	[36]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[37]
Omeprazole	DM471KJ	Cystic fibrosis	CA25	Approved	[38]

Drug(s) Affected By PTB-containing, cubilin and LRP1-interacting protein (PID1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fexofenadine	DM17ONX	Allergic rhinitis	CA08.0	Approved	[4]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[4]
Penbutolol	DM4ES8F	Hypertension	BA00-BA04	Approved	[4]
Nefazodone	DM4ZS8M	Major depressive disorder	6A70.3	Approved	[4]
Isoniazid	DM5JVS3	Latent tuberculosis infection		Approved	[4]
Amikacin	DM5PDRB	Bacteremia	1A73	Approved	[4]
Nevirapine	DM6HX9B	Human immunodeficiency virus infection	1C62	Approved	[4]
Promethazine	DM6I5GR	Hyperemesis gravidarum		Approved	[4]
Etodolac	DM6WJO9	Osteoarthritis	FA00-FA05	Approved	[4]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[39]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Norepinephrine transporter (NET)	TTAWNKZ	SC6A2_HUMAN	Inhibitor	[2]

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
P-glycoprotein 1 (ABCB1)	DTUGYRD	MDR1_HUMAN	Substrate	[3]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Antileukoproteinase (SLPI)	OTUNFUU8	SLPI_HUMAN	Gene/Protein Processing	[4]
Hepatocyte growth factor receptor (MET)	OT7K55MU	MET_HUMAN	Gene/Protein Processing	[4]
Phosphatidylcholine translocator ABCB4 (ABCB4)	OTE6PY83	MDR3_HUMAN	Gene/Protein Processing	[5]
Proepiregulin (EREG)	OTRM4NQY	EREG_HUMAN	Gene/Protein Processing	[4]
PTB-containing, cubilin and LRP1-interacting protein (PID1)	OT5YJ7FI	PCLI1_HUMAN	Gene/Protein Processing	[4]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7285).
• [2] Analgesic properties of intrathecally administered heterocyclic antidepressants. Pain. 1987 Mar;28(3):343-55.
• [3] Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. J Pharmacol Exp Ther. 2002 Dec;303(3):1029-37.
• [4] An in vitro coculture system of human peripheral blood mononuclear cells with hepatocellular carcinoma-derived cells for predicting drug-induced liver injury. Arch Toxicol. 2021 Jan;95(1):149-168. doi: 10.1007/s00204-020-02882-4. Epub 2020 Aug 20.
• [5] Evaluating the Role of Multidrug Resistance Protein 3 (MDR3) Inhibition in Predicting Drug-Induced Liver Injury Using 125 Pharmaceuticals. Chem Res Toxicol. 2017 May 15;30(5):1219-1229. doi: 10.1021/acs.chemrestox.7b00048. Epub 2017 May 4.
• [6] Augmentation effect of combination therapy of aripiprazole and antidepressants on forced swimming test in mice. Psychopharmacology (Berl). 2009 Sep;206(1):97-107.
• [7] Treatment of comorbid pain with serotonin norepinephrine reuptake inhibitors. CNS Spectr. 2008 Jul;13(7 Suppl 11):22-6.
• [8] Invivo antioxidant status: a putative target of antidepressant action. Prog Neuropsychopharmacol Biol Psychiatry. 2009 Mar 17;33(2):220-8.
• [9] Differential involvement of the norepinephrine, serotonin and dopamine reuptake transporter proteins in cocaine-induced taste aversion. Pharmacol Biochem Behav. 2009 Jul;93(1):75-81.
• [10] Clinically relevant drug interactions with new generation antidepressants and antipsychotics. Ther Umsch. 2009 Jun;66(6):485-92.
• [11] 2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6.
• [12] Antidepressants suppress production of the Th1 cytokine interferon-gamma, independent of monoamine transporter blockade. Eur Neuropsychopharmacol. 2006 Oct;16(7):481-90.
• [13] Multi-target therapeutics: when the whole is greater than the sum of the parts. Drug Discov Today. 2007 Jan;12(1-2):34-42.
• [14] Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
• [15] MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. Cancer Chemother Pharmacol. 2009 Jun;64(1):183-8.
• [16] Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
• [17] Folate transporter expression decreases in the human placenta throughout pregnancy and in pre-eclampsia. Pregnancy Hypertens. 2012 Apr;2(2):123-31.
• [18] Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8.
• [19] Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994 Jul 19;48(2):287-92.
• [20] Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. Ther Drug Monit. 2011 Apr;33(2):244-50.
• [21] Cannabidiol-induced transcriptomic changes and cellular senescence in human Sertoli cells. Toxicol Sci. 2023 Feb 17;191(2):227-238. doi: 10.1093/toxsci/kfac131.
• [22] Global gene expression analysis reveals differences in cellular responses to hydroxyl- and superoxide anion radical-induced oxidative stress in caco-2 cells. Toxicol Sci. 2010 Apr;114(2):193-203. doi: 10.1093/toxsci/kfp309. Epub 2009 Dec 31.
• [23] Functional gene expression profile underlying methotrexate-induced senescence in human colon cancer cells. Tumour Biol. 2011 Oct;32(5):965-76.
• [24] Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
• [25] Effects of ciglitazone and troglitazone on the proliferation of human stomach cancer cells. World J Gastroenterol. 2009 Jan 21;15(3):310-20.
• [26] Retinoid-induced epidermal hyperplasia is mediated by epidermal growth factor receptor activation via specific induction of its ligands heparin-binding EGF and amphiregulin in human skin in vivo. J Invest Dermatol. 2006 Apr;126(4):732-9. doi: 10.1038/sj.jid.5700202.
• [27] Transcriptional and Metabolic Dissection of ATRA-Induced Granulocytic Differentiation in NB4 Acute Promyelocytic Leukemia Cells. Cells. 2020 Nov 5;9(11):2423. doi: 10.3390/cells9112423.
• [28] ROS-dependent DNA damage contributes to crizotinib-induced hepatotoxicity via the apoptotic pathway. Toxicol Appl Pharmacol. 2019 Nov 15;383:114768. doi: 10.1016/j.taap.2019.114768. Epub 2019 Oct 19.
• [29] Antitumor action of the MET tyrosine kinase inhibitor crizotinib (PF-02341066) in gastric cancer positive for MET amplification. Mol Cancer Ther. 2012 Jul;11(7):1557-64. doi: 10.1158/1535-7163.MCT-11-0934. Epub 2012 Jun 22.
• [30] Antirheumatic drug response signatures in human chondrocytes: potential molecular targets to stimulate cartilage regeneration. Arthritis Res Ther. 2009;11(1):R15.
• [31] All-trans retinoic acid inhibits the cell proliferation but enhances the cell invasion through up-regulation of c-met in pancreatic cancer cells. Cancer Lett. 2005 Jun 28;224(2):303-10. doi: 10.1016/j.canlet.2004.10.016. Epub 2004 Dec 8.
• [32] [Reversal effect of MDR1 and MDR3 gene silencing on resistance of A2780/taxol cells to paclitaxel]. Zhonghua Fu Chan Ke Za Zhi. 2007 Jun;42(6):412-6.
• [33] 8-Methoxypsoralen disrupts MDR3-mediated phospholipids efflux and bile acid homeostasis and its relevance to hepatotoxicity. Toxicology. 2017 Jul 1;386:40-48. doi: 10.1016/j.tox.2017.05.011. Epub 2017 May 24.
• [34] Molecular mechanisms of hepatotoxic cholestasis by clavulanic acid: Role of NRF2 and FXR pathways. Food Chem Toxicol. 2021 Dec;158:112664. doi: 10.1016/j.fct.2021.112664. Epub 2021 Nov 9.
• [35] Global molecular effects of tocilizumab therapy in rheumatoid arthritis synovium. Arthritis Rheumatol. 2014 Jan;66(1):15-23.
• [36] Pharmacotoxicology of clinically-relevant concentrations of obeticholic acid in an organotypic human hepatocyte system. Toxicol In Vitro. 2017 Mar;39:93-103.
• [37] Species-specific toxicity of diclofenac and troglitazone in primary human and rat hepatocytes. Chem Biol Interact. 2009 Apr 15;179(1):17-24.
• [38] Evaluation of gene induction of drug-metabolizing enzymes and transporters in primary culture of human hepatocytes using high-sensitivity real-time reverse transcription PCR. Yakugaku Zasshi. 2002 May;122(5):339-61.
• [39] Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.